Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients

Alexandra J. van den Broeck, Marjanka K. Schmidt*, Laura J. van't Veer, Hester S. A. Oldenburg, Emiel J. Rutgers, Nicola S. Russell, Vincent T. H. B. M. Smit, Adri C. Voogd, Linetta B. Koppert, Sabine Siesling, Jan J. Jobsen, Pieter J. Westenend, Flora E. van Leeuwen, Rob A. E. M. Tollenaar

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective: To investigate the effects of different types of surgery on breast cancer prognosis in germline BRCA1/BRCA2 mutation carriers compared with noncarriers.

Summary of Background Data: Although breast-conserving therapy (breast-conserving surgery followed by radiotherapy) has been associated with more local recurrences than mastectomy, no differences in overall survival have been found in randomized trials performed in the general breast cancer population. Whether breast-conservation can be safely offered to BRCA1/2 mutation carriers is debatable.

Methods: The study comprised a cohort of women with invasive breast cancer diagnosed

Results: In noncarriers (N = 5820), as well as in BRCA1 (N = 191) and BRCA2 (N = 70) mutation carriers, approximately half of the patients received breast-conserving therapy. Patients receiving mastectomy followed by radiotherapy had prognostically worse tumor characteristics and more often received systemic therapy. After adjustment for these potential confounders, patients who received breast-conserving therapy had a similar overall survival compared with patients who received mastectomy, both in noncarriers (hazard ratio [HR] = 0.95, confidence interval [CI] = 0.85-1.07, P = 0.41) and BRCA1 mutation carriers (HR = 0.80, CI = 0.42-1.51, P = 0.50). Numbers for BRCA2 were insufficient to draw conclusions. The rate of local recurrences after breast-conserving therapy did not differ between BRCA1 carriers (10-year risk = 7.3%) and noncarriers (10-year risk = 7.9%).

Conclusion: Our results, together with the available literature, provide reassurance that breast-conserving therapy is a safe local treatment option to offer to BRCA1 mutation carriers with invasive breast cancer.

Original languageEnglish
Pages (from-to)364-372
Number of pages9
JournalAnnals of Surgery
Issue number2
Publication statusPublished - Aug 2019


  • BRCA1
  • BRCA2
  • breast cancer
  • breast-conserving therapy
  • mastectomy
  • prognosis
  • survival
  • RISK
  • 10-YEAR

Cite this